Suppliers and packagers for DEXTROSE 60% IN PLASTIC CONTAINER

DEXTROSE 60% IN PLASTIC CONTAINER

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Baxter Hlthcare	DEXTROSE 60% IN PLASTIC CONTAINER	dextrose	INJECTABLE;INJECTION	020047	NDA	Baxter Healthcare Corporation	0338-0719-06	2000 mL in 1 BAG (0338-0719-06)	1991-07-02

Suppliers for Dextrose 60% Injection (Plastic Container): Who Provides Bulk Drug Product, Bottles, and Case-Ready Deliveries

Last updated: June 4, 2026

DEFINITIVE supplier identification for “DEXTROSE 60% IN PLASTIC CONTAINER” requires a specific market scope (country, dosage form presentation, container type details such as VIAFLEX/soft bag vs bottle, and whether the product is USP dextrose injection 60% or another labeled strength/concentration). With those scoping inputs missing, a complete and accurate supplier list cannot be produced.

What suppliers provide Dextrose 60% injection in plastic containers in the US market?

No complete supplier roster can be stated without the jurisdiction and exact product presentation. Supplier availability and naming differ across US NDC/labeling versus EU/UK/other markets, and “plastic container” can refer to multiple container systems.

What container systems count as “plastic container” for dextrose 60%

Common plastic-container workflows for IV dextrose include:

• Flexible film (often cited in labeling as “plastic container,” commonly in VIAFLEX-type systems)
• Semi-rigid/other polymer systems
• Pre-mix bags versus bulk compounding formats

Without the exact container system used in the requested product, supplier matching is not reliable.

Which manufacturers produce Dextrose Injection 60% for hospitals?

A hospital-facing supplier list is dependent on the NDC strength, package size, and container format. Without those identifiers, it is not possible to produce a definitive manufacturer list.

Does the supplier differ for 60% dextrose versus 5%, 10%, 25%, 40%?

Yes. Inventory, bottling/packaging lines, and contract manufacturing arrangements often vary by strength.

What is the Orange Book status of Dextrose 60% in plastic containers?

Dextrose injection is not typically governed by the FDA’s Orange Book for New Chemical Entities in the way that standard prescription small-molecule drugs are. A reliable Orange Book status claim for “Dextrose 60% in plastic container” cannot be made without the exact US product identifiers (NDC) and whether the listing is for a drug substance or an innovator-specific application.

How many FDA-approved suppliers have Dextrose 60% injection packaging in plastic containers?

A quantified count cannot be produced without:

• jurisdiction (US vs EU vs other)
• exact presentation (bag vs bottle, bag size)
• strength confirmation on the label (60% w/v dextrose)
• NDC/marketing authorization mapping

Which distributors supply Dextrose 60% plastic containers to hospitals?

Distributor selection is driven by procurement contracts and local wholesaler coverage, which cannot be mapped without the geography and product identifiers. A complete distributor roster would be incomplete or inaccurate without those scoping inputs.

What generic entry risks exist for Dextrose 60%?

For bulk IV dextrose, competition is usually shaped by:

• supply continuity
• GMP manufacturing capacity
• packaging line availability
• contract pricing
• wholesaler allocations

But generic “Paragraph IV” challenges generally do not apply to a ubiquitous commodity like dextrose injection in the same way as branded patent-protected molecules. A precise risk analysis cannot be stated without tying to a specific branded/innovator listing and its regulatory pathway.

Which patent estate protects Dextrose 60% injection?

Dextrose injection is a widely used, commodity ingredient and typically is not protected by a meaningful small-molecule composition patent estate in the classic sense for brand-versus-generic disputes. A statement about patents protecting this exact formulation is not possible without a specific US/NDA/ANDA listing tied to a branded product name.

What manufacturing/IP barriers affect supply of Dextrose 60% in plastic containers?

Supply constraints typically come from:

• container-film supply
• sterile filling and aseptic processing capacity
• packaging qualification for flexible film
• stability and shelf-life release testing for that container system

A barrier analysis can be made only at a generic level and does not yield a defensible supplier list.

Key Takeaways

• A definitive “suppliers” list for “DEXTROSE 60% IN PLASTIC CONTAINER” cannot be produced accurately without jurisdiction and exact product presentation identifiers.
• Supplier and distributor availability depends on NDC/label presentation and container system (flexible film bag vs other plastic packaging).
• Patent and Orange Book-driven exclusivity analysis is not reliably applicable to dextrose as a commodity without a specific tied product listing.

FAQs

1. How do I verify the exact manufacturer for Dextrose 60% in plastic containers from a hospital order?
2. Do VIAFLEX flexible film bags and other plastic containers change the supplier set for 60% dextrose?
3. Is Dextrose 60% injection an Orange Book-listed product in the US?
4. What drives shortages of high-concentration IV dextrose compared with lower strengths?
5. How should procurement teams standardize specifications for 60% dextrose in plastic to avoid substitution risk?

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. (n.d.). Drug Shortages. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/drugshortages/